Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Medtecs International Yönetim

Yönetim kriter kontrolleri 2/4

Medtecs International's CEO'su William Yang, May2018 tarihinde atandı, in görev süresi 6.42 yıldır. şirketin hisselerinin 0.55% doğrudan sahiptir ve bu hisselerin değeri SGD 450.00K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.6 yıl ve 5.8 yıldır.

Anahtar bilgiler

William Yang

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	6.4yrs
CEO sahipliği	0.6%
Yönetim ortalama görev süresi	3.6yrs
Yönetim Kurulu ortalama görev süresi	5.8yrs

Son yönetim güncellemeleri

Recent updates

CEO

William Yang (41 yo)

6.4yrs

Görev süresi

Mr. Weiyuan Yang, also known as William, has been General Manager of Medtecs Taiwan Corporation since 2010. Mr. Yang has been Chief Executive Officer of Medtecs International Corporation Limited since May...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ker-Cheng Yang	Executive Chairman	26.9yrs	Veri yok	7.2% $ 5.5m
Weiyuan Yang	CEO & Deputy Chairman	6.4yrs	Veri yok	0.55% $ 417.0k
Yi-Ching Lin	Chief Financial Officer	2.8yrs	Veri yok	Veri yok
Chien Yang Wan	General Counsel	3.6yrs	Veri yok	Veri yok
Abdul Jabbar Bin Karam Din	Company Secretary	no data	Veri yok	Veri yok

3.6yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 546 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ker-Cheng Yang	Executive Chairman	26.9yrs	Veri yok	7.2% $ 5.5m
Weiyuan Yang	CEO & Deputy Chairman	11.1yrs	Veri yok	0.55% $ 417.0k
Chien-Chung Nieh	Independent Director	no data	Veri yok	Veri yok
Mui Choo Low	Lead Independent Non-Executive Director	less than a year	Veri yok	Veri yok
Zhao Yuhong	Independent Non-Executive Director	less than a year	Veri yok	Veri yok

5.8yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 546 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.8 yıldır).

Medtecs International Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Medtecs International Corporation Limited Changes to the Composition of the Board of Directors and Board Committees

Medtecs International Corporation Limited, Annual General Meeting, Apr 30, 2024

Medtecs International Corporation Limited, Annual General Meeting, Jun 30, 2023

Insufficient new directors

Insufficient new directors

Medtecs International Corporation Limited, Annual General Meeting, Apr 29, 2022

Recent updates

First half 2024 earnings released: US$0.007 loss per share (vs US$0.01 loss in 1H 2023)

Medtecs International Corporation Limited Changes to the Composition of the Board of Directors and Board Committees

Medtecs International Corporation Limited, Annual General Meeting, Apr 30, 2024

Full year 2023 earnings released

First half 2023 earnings released: US$0.01 loss per share (vs US$0.007 loss in 1H 2022)

New major risk - Revenue and earnings growth

Full year 2022 earnings released: US$0.052 loss per share (vs US$0.032 profit in FY 2021)

Medtecs International Corporation Limited, Annual General Meeting, Jun 30, 2023

Full year 2022 earnings released

Medtecs International Corporation Limited Provides Group Earnings Guidance for the Second Half of 2022 and for the Financial Year Ended 31 December 2022

Medtecs International Corporation Limited to Report Fiscal Year 2022 Results on Mar 01, 2023

Insufficient new directors

First half 2022 earnings released: EPS: US$0 (vs US$0.035 in 1H 2021)

Now 20% undervalued after recent price drop

Medtecs International Corporation Limited Provides Earnings Guidance for First Half of 2022

Medtecs International Corporation Limited Approves Final Dividend for the Financial Year Ended 31 December 2021, Payable on or Around 30 June 2022

Now 21% undervalued after recent price drop

Medtecs International Corporation Limited Declares Tax Exempt One-Tier Final Dividend for the Financial Year Ended 31 December 2021

Price target decreased to S$0.92

Insufficient new directors

Full year 2021 earnings released: EPS: US$0.032 (vs US$0.24 in FY 2020)

Medtecs International Corporation Limited, Annual General Meeting, Apr 29, 2022

Medtecs International Corporation Limited Recommends One-Tier, Tax Exempt Final Dividend for the Year Ended 31 December 2021

Full year 2021 earnings: Revenues miss analyst expectations

Insufficient new directors

Chief Financial Officer Wilfrido Candelaria Rodriguez has left the company

Medtecs International Corporation Limited Provides Earnings Guidance for the Fourth Quarter, Second Half and Full Year of Financial Year Ending 31 December 2021

Medtecs International Corporation Limited Launches A Line-Up of Face Masks for Children in Six Vibrant Colors on Amazon

CEO & Deputy Chairman recently bought S$287k worth of stock

CEO & Deputy Chairman recently bought S$420k worth of stock

Investor sentiment improved over the past week

CEO & Deputy Chairman recently bought S$479k worth of stock

Price target decreased to S$0.92

Consensus forecasts updated

Medtecs International Corporation Limited Provides Revenue Guidance for the Second Quarter Ending 30 June 2021

Upcoming dividend of US$0.042 per share

Independent Director has left the company

Medtecs International Corporation Limited Approves Tax Exempt One-Tier Final Dividend for the Year Ended December 31, 2020

Full year 2020 earnings released: EPS US$0.24 (vs US$0.002 in FY 2019)

Medtecs International Corporation Limited Announces Management Changes

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released

Wan Chien Yang Appoints as General Counsel of the Medtecs International Corporation Limited, Effective 1 March 2021

Medtecs International Corporation Limited Enters into A Letter of Intent with Enimmune Co., Ltd

CEO & Executive Director recently bought S$527k worth of stock

Market bids up stock over the past week

CEO & Executive Director recently bought S$921k worth of stock

New 90-day low: S$0.93

Market bids up stock over the past week

Earnings released

New 90-day high - S$0.90

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş